988 related articles for article (PubMed ID: 18318758)
1. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
Lawrie CH; Gal S; Dunlop HM; Pushkaran B; Liggins AP; Pulford K; Banham AH; Pezzella F; Boultwood J; Wainscoat JS; Hatton CS; Harris AL
Br J Haematol; 2008 May; 141(5):672-5. PubMed ID: 18318758
[TBL] [Abstract][Full Text] [Related]
2. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma.
Fang C; Zhu DX; Dong HJ; Zhou ZJ; Wang YH; Liu L; Fan L; Miao KR; Liu P; Xu W; Li JY
Ann Hematol; 2012 Apr; 91(4):553-9. PubMed ID: 21987025
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.
Roehle A; Hoefig KP; Repsilber D; Thorns C; Ziepert M; Wesche KO; Thiere M; Loeffler M; Klapper W; Pfreundschuh M; Matolcsy A; Bernd HW; Reiniger L; Merz H; Feller AC
Br J Haematol; 2008 Sep; 142(5):732-44. PubMed ID: 18537969
[TBL] [Abstract][Full Text] [Related]
4. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma.
Zhang T; Wang Q; Zhao D; Cui Y; Cao B; Guo L; Lu SH
Clin Sci (Lond); 2011 Nov; 121(10):437-47. PubMed ID: 21658006
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis.
Xu J; Wu C; Che X; Wang L; Yu D; Zhang T; Huang L; Li H; Tan W; Wang C; Lin D
Mol Carcinog; 2011 Feb; 50(2):136-42. PubMed ID: 21229610
[TBL] [Abstract][Full Text] [Related]
6. New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma.
Adams H; Tzankov A; Lugli A; Zlobec I
J Clin Pathol; 2009 Nov; 62(11):986-97. PubMed ID: 18977805
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value.
Gutiérrez A; Martínez-Serra J; Barceló B; Sampol A; Viñas L; González G; Bea MD; Amat JC; Martín J; Ramos R; Bautista A; Forteza-Rey J; Rodríguez J; Besalduch J
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):582-9. PubMed ID: 20201996
[TBL] [Abstract][Full Text] [Related]
8. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.
Kluiver J; Poppema S; de Jong D; Blokzijl T; Harms G; Jacobs S; Kroesen BJ; van den Berg A
J Pathol; 2005 Oct; 207(2):243-9. PubMed ID: 16041695
[TBL] [Abstract][Full Text] [Related]
9. Relevance of some serum biomarkers (E cadherin, GAGs & MDA in patients with diffuse large B-cell lymphoma.
Eissa LA; Esmaeel MI
Pak J Pharm Sci; 2008 Jan; 21(1):29-35. PubMed ID: 18166516
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
[TBL] [Abstract][Full Text] [Related]
12. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression.
Pu XX; Huang GL; Guo HQ; Guo CC; Li H; Ye S; Ling S; Jiang L; Tian Y; Lin TY
J Gastroenterol Hepatol; 2010 Oct; 25(10):1674-80. PubMed ID: 20880178
[TBL] [Abstract][Full Text] [Related]
13. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO
Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
[TBL] [Abstract][Full Text] [Related]
14. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
Resnick KE; Alder H; Hagan JP; Richardson DL; Croce CM; Cohn DE
Gynecol Oncol; 2009 Jan; 112(1):55-9. PubMed ID: 18954897
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
Bono P; Teerenhovi L; Joensuu H
Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
[TBL] [Abstract][Full Text] [Related]
16. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
Sakane-Ishikawa E; Nakatsuka S; Tomita Y; Fujita S; Nakamichi I; Takakuwa T; Sugiyama H; Fukuhara S; Hino M; Kanamaru A; Soma T; Tsukaguchi M; Igarashi K; Kanakura Y; Aozasa K;
J Clin Oncol; 2005 Nov; 23(31):8012-7. PubMed ID: 16258099
[TBL] [Abstract][Full Text] [Related]
18. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis.
Hasselblom S; Hansson U; Sigurdardottir M; Nilsson-Ehle H; Ridell B; Andersson PO
Pathol Int; 2008 Aug; 58(8):529-32. PubMed ID: 18705775
[TBL] [Abstract][Full Text] [Related]
20. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
